Community TR cohort
2026
Characteristics and Clinical Outcomes of Tricuspid Regurgitation in the Community: Insights from a Real-World Cohort of 180,977 Men and Women
In adults with tricuspid regurgitation in an Australian echocardiography database, moderate, severe and torrential tricuspid regurgitation were associated with progressively higher all-cause mortality compared with mild tricuspid regurgitation.
Résultat
Critère principal: Clinical outcomes by presence and severity of tricuspid regurgitation
Compared with mild TR, mortality risk was higher with moderate TR (adjusted HR 1.26; 95% CI 1.24-1.28), severe TR (adjusted HR 1.60; 95% CI 1.56-1.64) and torrential TR (adjusted HR 2.13; 95% CI 1.85-2.45). Overall mortality was 47.8%, with 45.3% in men and 39.0% in women with mild TR. Of the cohort, 73.7% had mild, 20.7% moderate and 5.6% severe TR (including 285 torrential cases). Isolated TR intervention was associated with a 74% drop in the risk of mortality (adjusted HR 0.26; 95% CI 0.19-0.35), but only 3.3% of men and 3.6% of women with severe TR had tricuspid valve repair. PH (adjusted HR 1.61), LHD (adjusted HR 1.21), RV (adjusted HR 1.16) and CIED (adjusted HR 1.05) TR subtypes independently predicted all-cause mortality. Median life-years lost were 7.1 years for both sexes with mild TR, 8.1 years for both with moderate TR and 8.1 years for men vs 6.1 years for women with severe TR.
- Sous-thème
- Tricuspid regurgitation
- Schéma
- Real-world community cohort of 180,977 men and women with echocardiography; characteristics and outcomes by tricuspid regurgitation
- Inclus
- 180 977 patients
- Source
- Hahn RT, et al. Presented at TCT 2026, 1 November. Reported by TCTMD (CRF). Not yet published.
Discussion et critique
This large echocardiographic cohort shows a graded rise in adjusted mortality from moderate to torrential tricuspid regurgitation, along with very low rates of tricuspid intervention even in severe disease. It is observational, so the lower mortality seen with isolated intervention cannot be read as a treatment effect, and the report does not establish whether TR drives outcomes or is a marker of heart failure. The discussant, Yan Topilsky, noted that there was no core lab or quantification, that the registry is not population based, which limits external validity, and that the adjustment did not include LVEF or kidney dysfunction. The results come from a news report of the presentation, and analyses of regression and progression were not yet presented.